Protara Therapeutics, Inc. (TARA)
Develops experimental cell therapies and nutritional treatments for cancer and rare diseases.
$3.94-0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+28.8%
The outlook
TARA trades at $3.94, well below both its 50- and 200-day moving averages, sitting near the lower end of its 52-week range. Analyst coverage shows a wide gap, with the average price target implying significant upside, though the overall sentiment leans bearish. The stock remains a speculative play with limited near-term momentum.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range20% of the way from its 52-week low to high
Price targetAvg target +574% vs current price
Analyst price target
~12-month · 7 analysts$26.57average target+574.4% vs now
Now $3.94
Low $24.00High $30.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$221.4M
52-wk high
$7.82
52-wk low
$2.97
50-day avg
$4.24
200-day avg
$5.31
Trailing P/E
—